721 results about "Regenerative medicine" patented technology

Tomography limitations in vivo due to incomplete, inconsistent and intricate measurements require solution of inverse problems. The new strategies disclosed in this application are capable of providing faster data acquisition, higher image quality, lower radiation dose, greater flexibility, and lower system cost. Such benefits can be used to advance research in cardiovascular diseases, regenerative medicine, inflammation, and nanotechnology. The present invention relates to the field of medical imaging. More particularly, embodiments of the invention relate to methods, systems, and devices for imaging, including tomography-based and MRI-based applications. For example, included in embodiments of the invention are compressive sampling based tomosynthesis methods, which have great potential to reduce the overall x-ray radiation dose for a patient. To name a few, compressive sensing based carbon nano-tube based interior tomosynthesis systems, tomography-based dynamic cardiac elastography systems, cardiac elastodynamic biomarkers from interior MR imaging, exact and stable interior ROI reconstructions for radial MRI, and interior reconstruction based ultrafast tomography systems are provided.

A system for the extraction, collection, processing and transplantation of cell subsets, including adult stem cells and platelets, in particular for tissue repair in regenerative medicine, comprises a set of disposable fluid-transport elements that are pre-connected or that include aseptic connectors for making interconnections between them in an aseptic manner or are adapted to be aseptically connected. The set usually includes three kits of disposable sterile elements, a collection kit, a processing kit, and a transplantation kit packaged in a blister pack on a support such as a tray, having one compartment for receiving each inter-connectable kit of the set. The set includes an extracting device, for example including a needle for bone puncture or vein puncture, for extracting bone marrow or other sources of cell subsets from a patient.

The present invention provides compositions and methods of using the compositions to alter the developmental potency of a cell. The present invention provides in vivo and ex vivo cell reprogramming and programming methods suitable for autologous cell therapy and regenerative medicine.

A neuronal differentiation promoting agent for neural stem cells comprising, as an active ingredient, at least one member selected from the group consisting of ω-3 unsaturated fatty acids and ω-6 unsaturated fatty acids having 18 to 22 carbon atoms, and derivatives thereof. The agent can be used for induction of differentiation of neural stem cells and is useful for treating and / or preventing a variety of neurological diseases, and in the fields of nerve transplantation and / or regenerative medicine for nerves.

The invention discloses a preparation method of multiple cross-linked polysaccharide injectable hydrogel. Modified water-soluble chitosan with carboxyl or hydroxyl groups as a first component and a hydroformylation-modified polysaccharide polymer or polysaccharide polymer mixer as a second component produce electrostatic action with each other and undergo a Schiff-base reaction to produce the hydrogel with a multiple cross-linked net structure. The multiple cross-linked polysaccharide injectable hydrogel has gelling time of 5-200s and has good mechanical properties. Through change of a chitosan and polysaccharide modification rate, a mole ratio of two components and solid content of hydrogel, gelling time, mechanical strength, microscopic morphology and water content are adjusted and controlled. The gel network contains a large amount of amino, carboxyl and aldehyde groups as active groups, the active groups can be bonded to drugs and proteins by covalent bonds, the multiple cross-linked polysaccharide injectable hydrogel as a novel medical material with excellent biocompatibility has a good application prospect in the fields of regeneration medical science, tissue engineering and drug controlled release.

Methods of ex-vivo expansion of fetal and / or adult progenitor, and umbilical cord blood, bone marrow or peripheral blood derived stem cells in bioreactors for bone marrow transplantation, transfusion medicine, regenerative medicine and gene therapy.

Culture media and methods for expanding and differentiating populations of stem cells and for obtaining organoids. Expanded cell populations and organoids obtainable by methods of the invention and their use in drug screening, toxicity assays and regenerative medicine.

The present disclosure features methods relating to conducting a stem cell technology business such as a regenerative medicine business based on induced pluripotent stem cells (iPSCs) and cells differentiated from iPSCs. The present disclosure also provides a database of iPSC-derived cells and methods of using the database for tracking customers and samples, as well as methods for marketing and running the business.

The methods and compositions described herein relate to novel 3-dimensional porous scaffolds useful for tissue re-generation, enhancement, or tissue repair. Electrospinning or other methods are used to create mats comprised of fibers that can be seeded with cells and subsequently rolled into a desired shape / form to replace a desired tissue.

In biology and biotechnology, electroporation is an important technique for introducing entities (DNA, RNAi, peptides, proteins, antibodies, genes, small molecules, nanoparticles, etc.) into cells. Applications range widely from genetic engineering to regenerative medicine to drug delivery. It has been demonstrated that the electrical currents flowing through cells can be used to monitor and control the process of electroporation for biological and artificial cells. In this application, a device and system are disclosed which allow precise monitoring and controlling electroporation of cells and cell layers, with examples shown using adherent cells grown on porous membranes.

An object of the present invention is to provide a process capable of producing a self-assembling peptide derivative that is useful in the fields of regenerative medicine and surgery in large quantities and in an economical and efficient manner. In particular, provided is a production process employing a combination of (i) a step of convergently constructing a sequence with use of a common repeating unit consisting of a specific amino acid sequence and (ii) a step of first isolating the peptide derivative as a disulfuric acid salt, a tetramethanesulfonic acid salt or a tetra(trifluoroacetic acid (TFA) salt), and then subjecting the peptide salt to a salt exchange reaction to yield a tetrahydrochloric acid salt.

A three-dimensional (3-D) culture “Petri-dish” for research in regenerative medicine, biotechnology and clinical translation is described. This 3-D perfusion culture dish is to advance in vitro culture tools from static 2-D to dynamic 3-D perfusion culture. Interwoven hollow fiber capillary membranes divide the “Petri-dish” culture space into a controllable 3-D pattern of different compartments, serving the functions of the organ's larger vasculature. These physically active scaffolds, which can be suitable for cell adhesion or cell aggregate immobilization, offer a supply of cells with high-performance mass exchange including gas supply and under perfusion conditions. In contrast to static and discontinuous medium supply, a dynamic culture can be achieved with continuous or alternating medium supply and integral oxygenation. They provide a more physiologic supply in the cell macro environment, including homeostasis of oxygen, pH, nutrition, soluble factors, and gradients of metabolites for the cells. Also, medium perfusion can be achieved. Consequently the invention was made for cultures at tissue density, especially stem cells and support cells, which strive to create their own stem cell niche.

The present inventors discovered that brain-localizing cells exist in the progenitor cell fraction of bone marrow cells. They also elucidated various characteristics of the brain-localizing cells. When these cells are infused into the bloodstream, they circulate in the blood and directly translocate into the cerebral parenchyma from the bloodstream. Furthermore, the present inventors succeeded in developing methods for efficiently preparing brain-localizing cells from bone marrow or bone marrow cells. These methods can be applied to less-invasive regenerative medicines targeting the brain and using autologous cells.

The present invention relates to a probe for selecting ES cells, which characteristically contains one of DNAs having base sequences depicted in SEQ ID Nos; 1, 2, 3, 4, 5, 6, 7 and 8, or DNAs having base sequences depicted in SEQ ID Nos; 9, 11, 13, 15, 17, 19, 21, 23 and 41 and a screening method of ES cell using this probe. Preparation of a probe for selecting ES cells becomes feasible by identifying plural gene with ES cell-specific expressions (ECAT genes) and using the information of the base sequences of these gene groups. Efficient selection of ES cell enables supply of a large amount of ES cell expected to be applicable to regenerative medicine.

The invention belongs to the technical field of biological materials and regenerative medicine, in particular to a porous stent with a network passage and a preparation method of the porous stent. A matrix material of the porous stent disclosed by the invention can be an inorganic material, such as ceramics, glass, carbon, and the like, can be a macromolecular material with self bonding property, dissolvability and plasticity and can be a composite material of inorganic and macromolecular materials. The preparation method comprises the following steps of: uniformly mixing the matrix material with a pore-forming agent and a network-shaped substance; when the matrix material is the inorganic material, removing the pore-forming agent and the network-shaped substance for preparing by a high-temperature sintering method; and when the matrix material is the macromolecular material or the complex of the macromolecular material and the inorganic material, preparing the porous stent with the network passage by adopting a normal-temperature mould pressing / particle leaching method. According to the porous stent disclosed by the invention, a network passage structure is constructed on a three-dimensional space structure, thus the communication among holes of the stent is increased, and beneficial space is provided for a vessel growing stent by the introduced passage.

The present invention provides compositions including a cell contacting surface or film comprising nanotopography of nanofibers, nanotubes, nanochannels, microchannels or microwells, which are capable of enhancing or promoting cell differentiation or cell viability. The compositions are useful as medical implants, including orthopedic implants, dental implants, cardiovascular implants, neurological implants, neurovascular implants, gastrointestinal implants, muscular implants, and ocular implants. The present invention also provides methods of treating a patient in need of such an implant.

Culture media and methods for expanding and differentiating populations of stem cells and for obtaining organoids. Expanded cell populations and organoids obtainable by methods of the invention and their use in drug screening, toxicity assays and regenerative medicine.

The invention discloses a bionic three-dimensional tissue engineering scaffold, which is formed by high molecular fibrous membrane-loaded active growth factors, or active growth factors loaded on a composite scaffold formed by a high molecular fibrous membrane and a macropore spongy layer. With the adoption of the bionic three-dimensional tissue engineering scaffold, the problem that the concentration of active molecules loaded with an emulsion electricity texture fibrous membrane is low; the emulsion electricity texture fibrous membrane is combined with a macropore spongy or a mixed electricity texture process, so that the load rate of the active factors can be greatly improved; parts of factors are retained in the fiber through an emulsion electricity texture core-shell structure, so that the effective control of releasing time is realized, and a repairing process is monitored for a long time; and the introduction of active molecules in the scaffold plays guiding and promoting functions for proliferating regenerative cells, directionally differentiating, migrating and adhering cells, and capturing stem cells to introduce regenerative functions of newly born tissues, so that a new path is provided for development of regenerative medicine industries.

The invention relates to a method for preparing a patterning nanofiber membrane by utilizing insulating receiving template static spinning. The method comprises the following specific steps: (1) dissolving high polymer in a solvent, and stirring until the high polymer is completely dissolved, so as to obtain a spinning solution; and (2) carrying out static spinning on the spinning solution, and taking an insulating substance with a topological structure on the surface as a static spinning receiving device, so as to obtain the patterning nanofiber membrane. According to the preparation method disclosed by the invention, the nanofiber membrane with various patterns can be prepared conveniently and quickly at low cost. Since the patterning nanofiber membrane obtained by the invention is accurate in pattern, controllable and good in repeatability, the patterning nanofiber membrane has good application prospect in the fields of industry and medicine, especially in the field of regenerative medicine based on tissue engineering.

A blood storage container suitable for quick and efficient production of a large amount of serum while ensuring high safety, and a method of separating blood and a regenerative medical process using the same are provided. In a blood component separator 1 for separating collected blood into a plurality of blood components and preserving them, the separator 1 including a blood reservoir 10 for reserving the blood and a component storage part 20 aseptically connected in an air-tight manner to this blood reservoir 10, to the aforementioned blood reservoir 10 being imparted a serum producing function to remove coagulation factors from the blood to an extent enabling use in practical applications as a serum, and the aforementioned component storage part 20 storing each blood component generated by separation of the blood in the blood reservoir 10.

A novel BC fermentation technique for controlling 3D shape, thickness and architecture of the entangled cellulose nano-fibril network is presented. The resultant nano-cellulose based structures are useful as biomedical implants and devices, are useful for tissue engineering and regenerative medicine, and for health care products. More particularly, embodiments of the present invention relate to systems and methods for the production and control of 3-D architecture and morphology of nano-cellulose biomaterials produced by bacteria using any biofabrication process, including the novel 3-D Bioprinting processes disclosed. Representative processes according to the invention involve control of the rate of production of biomaterial by bacteria achieved by meticulous control of the addition of fermentation media using a microfluidic system. In exemplary embodiments, the bacteria gradually grew up along the printed alginate structure that had been placed into the culture, incorporating it. After culture, the printed alginate structure was successfully removed revealing porosity where the alginate had been placed. Porosity and interconnectivity of pores in the resultant 3-D architecture can be achieved by porogen introduction using, e.g., ink-jet printer technology.

The invention relates to a biologically degradable composite material and to a process for the preparation thereof. The biologically degradable composite material according to the invention is preferably a bone reconstruction material which can be used in the field of regenerative medicine, especially as a temporary bone defect filler for bone regeneration.

A composition including delipidated, decellularized adipose tissue and delipidated, decellularized fascial tissue is provided. The composition may further include exogenous tissuegenic cells, an exogenous growth-inductive substance, and / or a carrier. The composition is suitable for implantation into a living body in plastic surgery procedures, including reconstructive or cosmetic surgery procedures, wound care procedures or other procedures of regenerative medicine. A method of preparing an acellular soft tissue-derived matrix from adipose tissue and fascial tissue is also provided. The method involves preparing a delipidated, decellularized adipose-derived matrix by delipidizing the adipose tissue and decellularizing the adipose tissue; preparing a delipidated, decellularized fascia-derived matrix by delipidizing the fascial tissue and decellularizing the fascial tissue; and combining the delipidated, decellularized adipose-derived matrix and the delipidated, decellularized fascia-derived matrix to produce said acellular soft tissue-derived matrix. The resulting Acellular soft tissue-derived matrix may be partially dried, substantially dried, or not dried.

The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.

A novel BC fermentation technique for controlling 3D shape, thickness and architecture of the entangled cellulose nano-fibril network is presented. The resultant nano-cellulose based structures are useful as biomedical implants and devices, are useful for tissue engineering and regenerative medicine, and for health care products. More particularly, embodiments of the present invention relate to systems and methods for the production and control of 3-D architecture and morphology of nano-cellulose biomaterials produced by bacteria using any biofabrication process, including the novel 3-D Bioprinting processes disclosed. Representative processes according to the invention involve control of the rate of production of biomaterial by bacteria achieved by meticulous control of the addition of fermentation media using a microfluidic system. In exemplary embodiments, the bacteria gradually grew up along the printed alginate structure that had been placed into the culture, incorporating it. After culture, the printed alginate structure was successfully removed revealing porosity where the alginate had been placed. Porosity and interconnectivity of pores in the resultant 3-D architecture can be achieved by porogen introduction using, e.g., ink-jet printer technology.

Disclosed is a method for production of a bio-derived scaffold for use in regenerative medicine, which has a bio-compatibility and biodegradability and can self-organize and grow without causing calcification. The method comprises the steps of partially fixing a biological soft tissue with glutaraldehyde by cross-linking and incubating the partially fixed tissue together with an elastase.

Disclosed is a method for distinguishing a mesenchymal stem cell comprising, using at least one gene selected from the genes having the nucleotide sequences indicated by the accession numbers shown in Table 1 as a distinguish marker, detecting the difference in expression of the distinguish marker between a mesenchymal stem cell and a connective tissue cell to distinguish the mesenchymal stem cell from the connective tissue cell. This method enables to distinguish an undifferentiated mesenchymal stem cell from other connective tissue cell such as fibroblasts, osteoblasts, chondrocytes and adipose cells with good accuracy. A mesenchymal stem cell given by this method or a composition comprising the mesenchymal stem sell can be used as a therapeutic for use in the regenerative medicine.

The invention provides degradation time controllable and breaking elongation adjustable medical degradable polyurethane, a preparation method thereof and an application of the polyurethane. By adjusting the proportion of components in the synthesis process of the polyurethane and selecting different chain extenders, the performances such as the degradation time, the breaking elongation, the strength, the lubricating property, hydrophily and hydrophobicity of the PU (polyurethane) can be controlled within a wide range, and the medical degradable polyurethane with different performances can be selected according to the requirements of regenerative medicine and medical instruments implanted into bodies.

The present invention is directed to compositions of fetal hematopoietic stem and progenitor cells and stromal (mesencymal) cells derived from second trimester (16-20 weeks gestation) miscarriages, that are isolated, processed and cryopreserved, and the therapeutic uses of such stem and progenitor cells upon application. Such compositions may be useful for hematopoietic reconstitution and / or replacement in patients with various diseases and metabolic disorders. The invention also relates to methods for collecting, isolating, processing and cryopreserving of the fetal stem and progenitor cells of the invention. Importantly, the invention meets an urgent need in regenerative medicine while at the same time ensures utility of the product compositions because it utilizes fetal materials from second trimester (16-20 weeks of gestation) spontaneously lost pregnancies which are free of moral or ethical burdens.

The present invention relates to populations and compositions of stem and progenitor cells derived from the umbilical cord, and methods of obtaining the same. In some embodiments, one or more entire umbilical cords or sections thereof are subjected to a process where a cell population is derived without prior removal of any blood vessel. The population may be derived using mechanical and chemical means. The presently disclosed process may be applied to a single umbilical cord or to a plurality of umbilical cords, for example, as a batch process. Optionally, this process includes removing some or all cord blood before deriving the population. In some embodiments, presently disclosed cell populations include mesenchymal stem cells derived from Wharton's jelly and endothelial progenitor cells derived from a wall of a blood vessel of an umbilical cord. Optionally, the cell population includes stem cells derived from cord blood. The presently disclosed cell populations and compositions may be banked and / or used in a number of clinical or other applications. Exemplary applications include but are not limited to applications related to regenerative medicine, for screening compounds, for research, and for gene therapy.